STEADY-STATE SERUM CONCENTRATIONS OF PRAVASTATIN AND DIGOXIN WHEN GIVEN IN COMBINATION

被引：17

作者：

TRISCARI, J ^{[1
]}

SWANSON, BN ^{[1
]}

WILLARD, DA ^{[1
]}

COHEN, AI ^{[1
]}

DEVAULT, A ^{[1
]}

PAN, HY ^{[1
]}

机构：

[1] MED CTR PRINCETON,PRINCETON,NJ

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 1993年 / 36卷 / 03期

关键词：

PRAVASTATIN; DIGOXIN; DRUG INTERACTIONS;

D O I：

10.1111/j.1365-2125.1993.tb04227.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Pravastatin is an HMG CoA reductase inhibitor used in the treatment of hypercholesterolaemia. The steady state pharmacokinetics of pravastatin (20 mg) and digoxin (0.2 mg) were evaluated in 18 healthy male subjects following the administration of each drug alone or in combination for 9 days. Serum and urine were collected for up to 48 h after the ninth dose in this open, randomized 3-way crossover study. Digoxin concentrations were measured by radioimmunoassay, and pravastatin and its metabolites, SQ 31,906 and SQ 31,945 were measured by GC-MS. Digoxin and pravastatin pharmacokinetics were unchanged following combined administration. Combination therapy with pravastatin and digoxin is unlikely to expose patients to additional risk compared with pravastatin alone.

引用

页码：263 / 265

页数：3

共 10 条

[1]

EVERETT DW, 1991, DRUG METAB DISPOS, V19, P740

[2] DETERMINATION OF PRAVASTATIN SODIUM AND ITS MAJOR METABOLITES IN HUMAN-SERUM PLASMA BY CAPILLARY GAS-CHROMATOGRAPHY NEGATIVE-ION CHEMICAL IONIZATION MASS-SPECTROMETRY [J].